MedTrace Logo

SARS-CoV-2 Seroprevalence Among Nursing Home Staff and Residents (COVID-19)

NCT04738695 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3008

Last updated 2023-11-24

No results posted yet for this study

Summary

Assessment of the seroprevalence and sero-incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) among Nursing Home (NH) residents and staff in Belgium.

Conditions

Interventions

DIAGNOSTIC_TEST

Point-of-care rapid anti-SARS-CoV-2 antibody test (Orient Gene Biotech) and Dry Blood Spot collection (Euroimmun)

Bimonthly finger pricks with collection of 1-10 drops of capillary blood for detection of anti-SARS-CoV-2 immune markers

Sponsors & Collaborators

  • KU Leuven

    collaborator OTHER

  • University of Liege

    collaborator OTHER

  • Universiteit Antwerpen

    collaborator OTHER

  • Sciensano

    lead OTHER_GOV

Principal Investigators

  • An De Sutter, Prof. Dr. · University Ghent

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2021-12-31
Completion
2022-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04738695 on ClinicalTrials.gov